Loading...
•
Dec 31, 2021
Day One Q4 2021 Earnings Report
Announced fourth quarter and full year 2021 financial results and highlighted recent corporate achievements.
Key Takeaways
Day One Biopharmaceuticals reported fourth quarter 2021 financial results, with cash and cash equivalents totaling $284.3 million. Research and development expenses were $11.2 million, and general and administrative expenses were $10.8 million. Net loss totaled $21.9 million for the quarter.
Initial data from FIREFLY-1 study with DAY101 (tovorafenib) expected in June 2022.
Targeted enrollment achieved in pivotal FIREFLY-1 study.
Topline results from pivotal FIREFLY-1 study expected in Q1 2023.
Current cash provides runway into 2024 and through multiple expected key clinical milestones.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...